Octant develops small-molecule correctors for protein-misfolding diseases with its Navigator platform, combining synthetic biology, generative chemistry, and AI in human cells; its lead program is in Phase 1/2.
Products & media
OCNT-980
A Phase 1 small-molecule corrector designed to restore rhodopsin folding and trafficking across mutations that cause autosomal-dominant retinitis pigmentosa.
Team
Jobs
See all jobs for Octant here.
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels
Series B
$80M